Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Svetlana Makhni becomes CFO and principal financial officer effective April 16, 2026.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Svetlana Makhni becomes CFO and principal financial officer effective April 16, 2026
- Allan Reine relinquishes principal financial officer duties while remaining CEO and principal executive officer
- Compensation includes $495,000 base salary, $40,000 sign-on bonus, and 40% target annual bonus
- Equity package totals 900,000 options, including 800,000 time-vested options and 100,000 milestone-based options
- Change-in-control severance includes 12 months’ salary, target bonus, benefits, and accelerated time-based equity vesting
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.